Allurion Technologies Inc. Q2 2025 Earnings Recap

ALUR Q2 2025 August 13, 2025

Get alerts when ALUR reports next quarter

Allurion Technologies reported a transformative second quarter, highlighting strategic pivots towards innovative obesity care solutions and a strong performance in key growth accounts.

Earnings Per Share Miss

$-1.28 vs $-0.65 est.

-96.9% surprise

Revenue Miss

3379000 vs 5175000 est.

-34.7% surprise

Market Reaction

1-Day -1.97%

5-Day -16.14%

30-Day -13.78%

See ALUR alongside your other holdings

Add to your portfolio — free

Key Takeaways

Transitioned distribution strategy to focus on partners promoting comprehensive obesity management, resulting in a 20% growth in targeted accounts.
Initiated development of a novel GLP-1 drug-eluting intragastric balloon, addressing adherence issues and enhancing treatment efficacy.
Submitted the final module of the PMA application on schedule, demonstrating significant weight loss efficacy exceeding preset target margins.
Resized sales force to prioritize high-performing accounts, positioning for long-term growth potential outside the U.S. market.
Launched a multicenter study in Europe to validate combination therapy's impact on weight loss and GLP-1 adherence, with enrollment expected by year-end.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ALUR on AllInvestView.

Next Q3 2025